{"entity":{"type":"insider","cik":"0001653881","url":"/insider/0001653881","json_url":"/insider/0001653881.json","name":"Goeltz II Robert C.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":20,"n_filings":12,"first":"2017-03-21","last":"2026-05-12","span_basis":"filed_date"},"name_variants":[{"name":"Goeltz II Robert C.","source":"filing","n_filings":12,"first_seen":"2017-03-21","last_seen":"2026-05-12"}],"transactions":[{"id":6197912,"accession":"0001653881-26-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001653881-26-000005","line_url":"/filing/0001653881-26-000005#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7763.0,"shares_display":"7,763","price_per_share":25.63,"price_display":"25.63","price_state":"stated","total_value":198965.69,"total_display":"198,965.69","total_whole":"198,966","shares_owned_after":84161.0,"shares_owned_after_display":"84,161","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-11","filed_date":"2026-05-12","scope":"insider"},{"id":5778053,"accession":"0001610717-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001610717-26-000002","line_url":"/filing/0001610717-26-000002#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6552.0,"shares_display":"6,552","price_per_share":23.38,"price_display":"23.38","price_state":"stated","total_value":153185.76,"total_display":"153,185.76","total_whole":"153,186","shares_owned_after":67924.0,"shares_owned_after_display":"67,924","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-31","filed_date":"2026-01-02","scope":"insider"},{"id":4603388,"accession":"0001653881-25-000011","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001653881-25-000011","line_url":"/filing/0001653881-25-000011#line-2","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5960.0,"shares_display":"5,960","price_per_share":22.1595,"price_display":"22.16","price_state":"stated","total_value":132070.62,"total_display":"132,070.62","total_whole":"132,071","shares_owned_after":74476.0,"shares_owned_after_display":"74,476","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-17","filed_date":"2025-12-18","scope":"insider"},{"id":4603383,"accession":"0001653881-25-000011","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001653881-25-000011","line_url":"/filing/0001653881-25-000011#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6702.0,"shares_display":"6,702","price_per_share":21.8843,"price_display":"21.88","price_state":"stated","total_value":146668.5786,"total_display":"146,668.58","total_whole":"146,669","shares_owned_after":80436.0,"shares_owned_after_display":"80,436","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-16","filed_date":"2025-12-18","scope":"insider"},{"id":4677925,"accession":"0001653881-25-000007","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001653881-25-000007","line_url":"/filing/0001653881-25-000007#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":25.0,"price_display":"25.00","price_state":"stated","total_value":125000.0,"total_display":"125,000.00","total_whole":"125,000","shares_owned_after":87138.0,"shares_owned_after_display":"87,138","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-26","filed_date":"2025-11-26","scope":"insider"},{"id":4677918,"accession":"0001653881-25-000005","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001653881-25-000005","line_url":"/filing/0001653881-25-000005#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5000.0,"shares_display":"5,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":100000.0,"total_display":"100,000.00","total_whole":"100,000","shares_owned_after":92138.0,"shares_owned_after_display":"92,138","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-28","filed_date":"2025-10-29","scope":"insider"},{"id":4743534,"accession":"0001724521-25-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001724521-25-000002","line_url":"/filing/0001724521-25-000002#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3594.0,"shares_display":"3,594","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":53910.0,"total_display":"53,910.00","total_whole":"53,910","shares_owned_after":60138.0,"shares_owned_after_display":"60,138","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-12-31","filed_date":"2025-01-03","scope":"insider"},{"id":2366600,"accession":"0001724521-24-000009","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001724521-24-000009","line_url":"/filing/0001724521-24-000009#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2004.0,"shares_display":"2,004","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":40080.0,"total_display":"40,080.00","total_whole":"40,080","shares_owned_after":51831.0,"shares_owned_after_display":"51,831","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-02","filed_date":"2024-01-04","scope":"insider"},{"id":8254170,"accession":"0001209191-23-035740","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-23-035740","line_url":"/filing/0001209191-23-035740#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4049.0,"shares_display":"4,049","price_per_share":20.04,"price_display":"20.04","price_state":"stated","total_value":81141.96,"total_display":"81,141.96","total_whole":"81,142","shares_owned_after":59392.0,"shares_owned_after_display":"59,392","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-07","filed_date":"2023-06-09","scope":"insider"},{"id":6498072,"accession":"0001209191-22-061762","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-061762","line_url":"/filing/0001209191-22-061762","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2453.0,"shares_display":"2,453","price_per_share":30.749926620464738,"price_display":"30.75","price_state":"stated","total_value":75429.57,"total_display":"75,429.57","total_whole":"75,430","shares_owned_after":11953.0,"shares_owned_after_display":"11,953","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-16","filed_date":"2022-12-16","scope":"insider","n_lines":2},{"id":5262221,"accession":"0001209191-21-070565","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-070565","line_url":"/filing/0001209191-21-070565","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":621.0,"shares_display":"621","price_per_share":40.35552045088567,"price_display":"40.36","price_state":"stated","total_value":25060.7782,"total_display":"25,060.78","total_whole":"25,061","shares_owned_after":7019.0,"shares_owned_after_display":"7,019","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-17","filed_date":"2021-12-20","scope":"insider","n_lines":4},{"id":5262209,"accession":"0001209191-21-070565","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-070565","line_url":"/filing/0001209191-21-070565","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":485.0,"shares_display":"485","price_per_share":39.825212164948454,"price_display":"39.83","price_state":"stated","total_value":19315.2279,"total_display":"19,315.23","total_whole":"19,315","shares_owned_after":7771.0,"shares_owned_after_display":"7,771","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-16","filed_date":"2021-12-20","scope":"insider","n_lines":2},{"id":2557763,"accession":"0001209191-20-049846","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-20-049846","line_url":"/filing/0001209191-20-049846#line-1","is_derivative":false,"issuer_cik":"0001653881","issuer_name":"Arcus Biosciences, Inc.","issuer_ticker":"RCUS","issuer_name_source":null,"issuer_url":"/issuer/0001653881","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":21.5697,"price_display":"21.57","price_state":"stated","total_value":107848.5,"total_display":"107,848.50","total_whole":"107,849","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-09-09","filed_date":"2020-09-09","scope":"insider"},{"id":4894990,"accession":"0001140361-17-012870","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001140361-17-012870","line_url":"/filing/0001140361-17-012870","is_derivative":false,"issuer_cik":"0001501989","issuer_name":"CytomX Therapeutics, Inc.","issuer_ticker":"CTMX","issuer_name_source":null,"issuer_url":"/issuer/0001501989","owner_cik":"0001653881","owner_name":"Goeltz II Robert C.","owner_display_name":"Goeltz II Robert C.","owner_url":"/insider/0001653881","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":21517.0,"shares_display":"21,517","price_per_share":19.814100478691266,"price_display":"19.81","price_state":"stated","total_value":426340.0,"total_display":"426,340.00","total_whole":"426,340","shares_owned_after":9789.0,"shares_owned_after_display":"9,789","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-20","filed_date":"2017-03-21","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":20,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":19,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":20},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001724521","name":"Arcus Biosciences, Inc.","url":"/issuer/0001724521","role":"Officer (Chief Financial Officer)","n_filings":11,"first_seen":"2020-09-09","last_seen":"2026-05-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001501989","name":"CytomX Therapeutics, Inc.","url":"/issuer/0001501989","role":"Officer (Chief Financial Officer)","n_filings":1,"first_seen":"2017-03-21","last_seen":"2017-03-21"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001653881","retrieved_at":"2026-08-27T11:14:35+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-26","last_ingest":"2026-08-27T05:24:39.644631+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}